Inventage Lab specializes in advanced drug delivery systems, leveraging innovative technologies such as Laminar-FLUIDigm™ and microfluidics. Their proprietary platform, Laminar-FLUIDigm™, integrates microfluidics into pharmaceutical manufacturing, enabling the development of unique drug formulations. This technology allows for precise control over the characteristics of microspheres used in long-acting injectable medications, optimizing parameters such as particle size and porosity. By developing their own engineering and optimization processes, Inventage Lab has created a flexible manufacturing system that minimizes raw material loss and allows for easy adjustment of batch sizes, setting them apart from traditional pharmaceutical companies.

Additionally, Inventage Lab employs the IVL-GeneFluidic® platform, which focuses on the formulation and manufacturing of lipid nanoparticles (LNP) for mRNA vaccine delivery. This technology addresses the challenge of mRNA stability by encapsulating it within lipid particles, forming a protective structure that ensures effective delivery into the human body. The company has developed a method to produce LNPs that can encapsulate 95-98% of mRNA, facilitating large-scale production. Through these advanced technologies, Inventage Lab aims to enhance the efficacy and safety of drug delivery, contributing significantly to the fields of biotechnology and pharmaceuticals.

South Korea

Inventage Lab has the technology to mass-produce micro/nano drug delivery systems using microfluidics technology. Sustained-release injectables using polymeric microspheres have been commercialized, and lipid nano delivery systems such as liposome and LNP are now being manufactured.

Inventage Lab

Company Details